As Sanofi Exits Diabetes R&D, Meaning Of ‘Diabetes R&D’ Blurs
Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.
